A2A overview

iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference Two Phase 1 trials to start in 2018 for A 2A receptor antagonist and IDO1 inhibitor Gosselies, Belgium - February 9, 2018 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A 2A antagonist and anti-TIGIT antibody programs in two oral presentations at the...

iTeos Therapeutics to Present Data for Novel A 2A Receptor Antagonist at American Association for Cancer Research Annual Meeting Gosselies, Belgium - April 3, 2017 -- iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, will present preclinical data for its A 2A receptor antagonist, which inhibits the immune suppressive function of adenosine, at the American Association for Cancer Research (AACR) Annual Meeting. The poster titled, 'A novel adenosine A 2A...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar...